Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Change in Cash (2020 - 2025)

Agilon Health's Change in Cash history spans 6 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 94.94% year-over-year to $2.0 million; the TTM value through Dec 2025 reached -$20.1 million, down 125.33%, while the annual FY2025 figure was -$20.1 million, 125.33% down from the prior year.
  • Change in Cash reached $2.0 million in Q4 2025 per AGL's latest filing, up from $268000.0 in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $1.0 billion in Q2 2021 to a low of -$352.6 million in Q2 2022.
  • Average Change in Cash over 5 years is $1.7 million, with a median of -$21.1 million recorded in 2021.
  • Peak YoY movement for Change in Cash: skyrocketed 12858.01% in 2021, then tumbled 1408.62% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$41.1 million in 2021, then tumbled by 38.25% to -$56.8 million in 2022, then fell by 13.05% to -$64.2 million in 2023, then soared by 162.4% to $40.1 million in 2024, then crashed by 94.94% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for AGL's Change in Cash are $2.0 million (Q4 2025), $268000.0 (Q3 2025), and $32.8 million (Q2 2025).